A Review of Ocular Complications Associated with Medications Used for Anxiety, Depression, and Stress

References

• Wu T, Jia X, Shi H, et al. Prevalence of mental health problems during the COVID-19 pandemic: a systematic review and meta-analysis. J Affect Disord. 2021;281:91–98. doi:10.1016/j.jad.2020.11.117
   PubMed Web of Science ®Google Scholar
• Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395:912–920.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299–2312.
   PubMed Web of Science ®Google Scholar
• Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs. 2010;24:501–526.
   PubMed Web of Science ®Google Scholar
• Brett J, Karanges EA, Daniels B, et al. Psychotropic medication use in Australia, 2007 to 2015: changes in annual incidence, prevalence and treatment exposure. Aust N Z J Psychiatry. 2017;51:990–999.
   PubMed Web of Science ®Google Scholar
• Keller MB. Long-term treatment strategies in affective disorders. Psychopharmacol Bull. 2002;36(Suppl 2):36–48.
   PubMedGoogle Scholar
• van Dijk HG, Dapper EA, Vinkers CH. SSRIs and depressive symptoms in schizophrenia: a systematic review. Tijdschr Psychiatr. 2017;59:40–46.
   PubMedGoogle Scholar
• Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother. 2016;16:131–144. doi:10.1586/14737175.2016.1135735
   PubMed Web of Science ®Google Scholar
• Licht RW. Lithium: still a major option in the management of bipolar disorder. CNS Neurosci Ther. 2012;18:219–226. doi:10.1111/j.1755-5949.2011.00260.x
   PubMed Web of Science ®Google Scholar
• Park JSY, Sharma RA, Sharma V. Ophthalmic adverse effects of lithium. Int Clin Psychopharmacol. 2020;35:69–73. doi:10.1097/YIC.0000000000000295
   PubMed Web of Science ®Google Scholar
• Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157:1552–1562.
   PubMed Web of Science ®Google Scholar
• Huider F, Milaneschi Y, van der Zee MD, et al. Major depressive disorder and lifestyle: correlated genetic effects in extended twin pedigrees. Genes. 2021;12:1509.
   PubMed Web of Science ®Google Scholar
• Park C, Rosenblat JD, Brietzke E, et al. Stress, epigenetics and depression: a systematic review. Neurosci Biobehav Rev. 2019;102:139–152.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhao Y, Wang Y, et al. The effects of psychological stress on depression. Curr Neuropharmacol. 2015;13:494–504.
   PubMed Web of Science ®Google Scholar
• Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085–1098.
   PubMed Web of Science ®Google Scholar
• Pitsillou E, Bresnehan SM, Kagarakis EA, et al. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression. Mol Biol Rep. 2020;47:753–770.
   PubMed Web of Science ®Google Scholar
• Mullins N, Lewis CM. Genetics of depression: progress at last. Curr Psychiatry Rep. 2017;19:43.
   PubMed Web of Science ®Google Scholar
• Mondal AC, Fatima M. Direct and indirect evidences of BDNF and NGF as key modulators in depression: role of antidepressants treatment. Int J Neurosci. 2019;129:283–296.
   PubMed Web of Science ®Google Scholar
• Zhang JC, Yao W, Hashimoto K. Brain-derived neurotrophic factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol. 2016;14:721–731.
   PubMed Web of Science ®Google Scholar
• Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–555.
   PubMed Web of Science ®Google Scholar
• Ménard C, Hodes GE, Russo SJ. Pathogenesis of depression: insights from human and rodent studies. Neuroscience. 2016;321:138–162.
   PubMed Web of Science ®Google Scholar
• Caviedes A, Lafourcade C, Soto C, et al. BDNF/NF-κB signaling in the neurobiology of depression. Curr Pharm Des. 2017;23:3154–3163.
   PubMed Web of Science ®Google Scholar
• Lino de Oliveira C, Bolzan JA, Surget A, et al. Do antidepressants promote neurogenesis in adult hippocampus? A systematic review and meta-analysis on naive rodents. Pharmacol Ther. 2020;210:107515.
   PubMed Web of Science ®Google Scholar
• Kohl C, Wang XD, Grosse J, et al. Hippocampal neuroligin-2 links early-life stress with impaired social recognition and increased aggression in adult mice. Psychoneuroendocrinology. 2015;55:128–143.
   PubMed Web of Science ®Google Scholar
• Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60(Suppl 4):4–13.
   PubMed Web of Science ®Google Scholar
• Lochmann D, Richardson T. Selective serotonin reuptake inhibitors. Handb Exp Pharmacol. 2019;250:135–144.
   PubMedGoogle Scholar
• Jakubovski E, Johnson JA, Nasir M, et al. Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders. Depress Anxiety. 2019;36:198–212.
   PubMed Web of Science ®Google Scholar
• Locher C, Koechlin H, Zion SR, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74:1011–1020.
   PubMed Web of Science ®Google Scholar
• Sigel E, Ernst M. The benzodiazepine binding sites of GABAA receptors. Trends Pharmacol Sci. 2018;39:659–671.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Associoation. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. Arlington, VA, US: American Psychiatric Publishing, Inc.; 2013.
   Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:617–627.
   PubMed Web of Science ®Google Scholar
• Nowels MA, VanderWielen LM. Comorbidity indices: a call for the integration of physical and mental health. Prim Health Care Res Dev. 2018;19:96–98.
   PubMed Web of Science ®Google Scholar
• Giacobbe P, Flint A. Diagnosis and management of anxiety disorders. Continuum (Minneap, Minn). 2018;24:893–919.
   PubMedGoogle Scholar
• Giotakos O. Neurobiology of emotional trauma. Psychiatriki. 2020;31:162–171.
   PubMedGoogle Scholar
• Ehret M. Treatment of posttraumatic stress disorder: focus on pharmacotherapy. Ment Health Clin. 2019;9:373–382.
   PubMedGoogle Scholar
• Miguel A, Henriques F, Azevedo LF, et al. Ophthalmic adverse drug reactions to systemic drugs: a systematic review. Pharmacoepidemiol Drug Saf. 2014;23:221–233.
   PubMed Web of Science ®Google Scholar
• Rief W, Nestoriuc Y, von Lilienfeld-Toal A, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf. 2009;32:1041–1056.
   PubMed Web of Science ®Google Scholar
• Acan D, Kurtgoz P. Influence of selective serotonin reuptake inhibitors on ocular surface. Clin Exp Optom. 2017;100:83–86.
   PubMed Web of Science ®Google Scholar
• Işik-Ulusoy S, Ulusoy MO. Influence of different antidepressants on ocular surface in patients with major depressive disorder. J Clin Psychopharmacol. 2021;41:49–52.
   PubMed Web of Science ®Google Scholar
• Koçer E, Koçer A, Özsütçü M, et al. Dry eye related to commonly used new antidepressants. J Clin Psychopharmacol. 2015;35:411–413.
   PubMed Web of Science ®Google Scholar
• van der Vaart R, Weaver MA, Lefebvre C, et al. The association between dry eye disease and depression and anxiety in a large population-based study. Am J Ophthalmol. 2015;159:470–474.
   PubMed Web of Science ®Google Scholar
• Galor A, Feuer W, Lee DJ, et al. Prevalence and risk factors of dry eye syndrome in a United States veterans affairs population. Am J Ophthalmol. 2011;152:377–384.e372.
   PubMed Web of Science ®Google Scholar
• Wen W, Wu Y, Chen Y, et al. Dry eye disease in patients with depressive and anxiety disorders in Shanghai. Cornea. 2012;31:686–692.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yin Y, Yue L, et al. Selective serotonin reuptake inhibitors aggravate depression-associated dry eye via activating the NF-κB pathway. Invest Ophthalmol Vis Sci. 2019;60:407–419.
   PubMed Web of Science ®Google Scholar
• Wan KH, Chen LJ, Young AL. Depression and anxiety in dry eye disease: a systematic review and meta-analysis. Eye (Lond). 2016;30:1558–1567.
   PubMed Web of Science ®Google Scholar
• Becker C, Jick SS, Meier CR. Selective serotonin reuptake inhibitors and cataract risk: a case-control analysis. Ophthalmology. 2017;124:1635–1639.
   PubMed Web of Science ®Google Scholar
• Chou PH, Chu CS, Chen YH, et al. Antidepressants and risk of cataract development: a population-based, nested case-control study. J Affect Disord. 2017;215:237–244.
   PubMed Web of Science ®Google Scholar
• Erie JC, Brue SM, Chamberlain AM, et al. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. Am J Ophthalmol. 2014;158:192–197.e191.
   PubMed Web of Science ®Google Scholar
• Etminan M, Mikelberg FS, Brophy JM. Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study. Ophthalmology. 2010;117:1251–1255.
   PubMed Web of Science ®Google Scholar
• Klein BEK, Klein R, Lee KE, et al. Drug use and five-year incidence of age-related cataracts: the Beaver Dam Eye Study. Ophthalmology. 2001;108:1670–1674.
   PubMed Web of Science ®Google Scholar
• Zanon-Moreno V, Melo P, Mendes-Pinto MM, et al. Serotonin levels in aqueous humor of patients with primary open-angle glaucoma. Mol Vis. 2008;14:2143–2147.
   PubMed Web of Science ®Google Scholar
• Kisilevsky E, Margolin EA. Case of rapid bilateral cataract development in teenager using selective serotonin reuptake inhibitors. Can J Ophthalmol. 2014;49:e114–115.
   PubMed Web of Science ®Google Scholar
• Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. Evid Based Ment Health. 2017;20:27.
   PubMed Web of Science ®Google Scholar
• Symes RJ, Etminan M, Mikelberg FS. Risk of angle-closure glaucoma with bupropion and topiramate. JAMA Ophthalmol. 2015;133:1187–1189.
   PubMed Web of Science ®Google Scholar
• Chen HY, Lin CL, Lai SW, et al. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry. 2016;77:e692–696.
   PubMed Web of Science ®Google Scholar
• Zheng W, Dryja TP, Wei Z, et al. Systemic medication associations with presumed advanced or uncontrolled primary open-angle glaucoma. Ophthalmology. 2018;125:984–993.
   PubMed Web of Science ®Google Scholar
• Wu A, Khawaja AP, Pasquale LR, et al. A review of systemic medications that may modulate the risk of glaucoma. Eye (Lond). 2020;34:12–28.
   PubMed Web of Science ®Google Scholar
• Stein JD, Talwar N, Kang JH, et al. Bupropion use and risk of open-angle glaucoma among enrollees in a large U.S. managed care network. PLoS One. 2015;10:e0123682.
   PubMed Web of Science ®Google Scholar
• Masís M, Kakigi C, Singh K, et al. Association between self-reported bupropion use and glaucoma: a population-based study. Br J Ophthalmol. 2017;101:525–529.
   PubMed Web of Science ®Google Scholar
• Barow E, Schneider SA, Bhatia KP, et al. Oculogyric crises: etiology, pathophysiology and therapeutic approaches. Parkinsonism Relat Disord. 2017;36:3–9.
   PubMed Web of Science ®Google Scholar
• Solberg M, Koht J. Oculogyric crises. Tremor Other Hyperkinet Mov (NY). 2017;7:491.
   PubMed Web of Science ®Google Scholar
• Kahraman N, Durmaz O, Durna MM. Mirtazapine-induced acute angle closure. Indian J Ophthalmol. 2015;63:539–540.
   PubMed Web of Science ®Google Scholar
• Dorell K, Cohen MA, Huprikar SS, et al. Citalopram-induced diplopia. Psychosomatics. 2005;46:91–93.
   PubMed Web of Science ®Google Scholar
• Alao A, Lewkowicz C. Seeing double: sertraline and diplopia: a case report. Int J Psychiatry Med. 2015;49:107–110.
   PubMed Web of Science ®Google Scholar
• Bicer T, Kosker M, Celikay O, et al. A case of retrobulbar optic neuritis caused by duloxetine. Cutan Ocul Toxicol. 2016;35:251–253.
   PubMed Web of Science ®Google Scholar
• Shifera AS, Leoncavallo A, Sherwood M. Probable association of an attack of bilateral acute angle-closure glaucoma with duloxetine. Ann Pharmacother. 2014;48:936–939.
   PubMed Web of Science ®Google Scholar
• Botha VE, Bhikoo R, Merriman M. Venlafaxine-induced intraocular pressure rise in a patient with open angle glaucoma. Clin Exp Ophthalmol. 2016;44:734–735.
   PubMed Web of Science ®Google Scholar
• Varatharaj A, Moran J. Pendular nystagmus associated with venlafaxine overdose: a forme fruste of the serotonin syndrome? BMJ Case Rep. 2014;2014:bcr2013202106.
   PubMedGoogle Scholar
• Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020;11:595584.
   PubMed Web of Science ®Google Scholar
• Szabadi E, Gaszner P, Bradshaw CM. Interaction of desipramine and amitriptyline with adrenergic mechanisms in the human iris in vivo. Eur J Clin Pharmacol. 1981;19:403–408.
   PubMed Web of Science ®Google Scholar
• Ciobanu AM, Dionisie V, Neagu C, et al. Psychopharmacological treatment, intraocular pressure and the risk of glaucoma: a review of literature. J Clin Med. 2021;10:2947.
   PubMed Web of Science ®Google Scholar
• Lucca JM, Ramesh M, Parthasarathi G, et al. Lorazepam-induced diplopia. Indian J Pharmacol. 2014;46:228–229.
   PubMed Web of Science ®Google Scholar
• Hassan Basri M, Khoo CS, Che Hamzah J. Dilated pupils in an anxious patient. Acta Neurol Belg. 2021;121:573–574.
   PubMed Web of Science ®Google Scholar
• Attaway A, Sroujieh L, Mersfelder TL, et al. “Ping-pong gaze” secondary to monoamine oxidase inhibitor overdose. J Pharmacol Pharmacother. 2016;7:34–37.
   PubMedGoogle Scholar
• Kawalec P, Cierniak A, Pilc A, et al. Pregabalin for the treatment of social anxiety disorder. Expert Opin Investig Drugs. 2015;24:585–594.
   PubMed Web of Science ®Google Scholar
• Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017;32:49–55.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826–836.
   PubMed Web of Science ®Google Scholar
• Tanyıldız B, Kandemir B, Mangan MS, et al. Bilateral serous macular detachment after attempted suicide with pregabalin. Turk J Ophthalmol. 2018;48:254–257.
   PubMedGoogle Scholar
• Mousailidis G, Papanna B, Salmon A, et al. Pregabalin induced visual hallucinations - a rare adverse reaction. BMC Pharmacol Toxicol. 2020;21:16.
   PubMed Web of Science ®Google Scholar
• Browne MJ, Zakrzewski H, Carleton B, et al. Association of gabapentin or pregabalin use and incidence of acute angle-closure glaucoma. J Glaucoma. 2019;28:777–779. doi:10.1097/IJG.0000000000001330
   PubMed Web of Science ®Google Scholar
• Van Rheenen TE, Meyer D, Neill E, et al. Mental health status of individuals with a mood-disorder during the COVID-19 pandemic in Australia: initial results from the COLLATE project. J Affect Disord. 2020;275:69–77. doi:10.1016/j.jad.2020.06.037
   PubMed Web of Science ®Google Scholar
• Baxter AJ, Scott KM, Ferrari AJ, et al. Challenging the myth of an “epidemic” of common mental disorders: trends in the global prevalence of anxiety and depression between 1990 and 2010. Depress Anxiety. 2014;31:506–516. doi:10.1002/da.22230
   PubMed Web of Science ®Google Scholar
• Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999;37:457–470. doi:10.2165/00003088-199937060-00002
   PubMed Web of Science ®Google Scholar
• Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86:184–192. doi:10.1542/peds.86.2.184
   PubMed Web of Science ®Google Scholar
• Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23(8):2087. doi:10.3390/molecules23082087
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41. doi:10.1016/S0140-6736(08)61764-X
   PubMed Web of Science ®Google Scholar
• Milaneschi Y, Simmons WK, van Rossum EFC, et al. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24:18–33.
   PubMed Web of Science ®Google Scholar
• Fluharty M, Taylor AE, Grabski M, et al. The association of cigarette smoking with depression and anxiety: a systematic review. Nicotine Tob Res. 2017;19:3–13. doi:10.1093/ntr/ntw140
   PubMed Web of Science ®Google Scholar
• Piper ME, Kenford S, Fiore MC, et al. Smoking cessation and quality of life: changes in life satisfaction over 3 years following a quit attempt. Ann Behav Med. 2012;43:262–270. doi:10.1007/s12160-011-9329-2
   PubMed Web of Science ®Google Scholar
• Karimi S, Arabi A, Shahraki T. Alcohol and the Eye. J Ophthalmic Vis Res. 2021;16:260–270. doi:10.18502/jovr.v16i2.9089
   PubMed Web of Science ®Google Scholar
• Davis L, Uezato A, Newell JM, et al. Major depression and comorbid substance use disorders. Curr Opin Psychiatry. 2008;21:14–18. doi:10.1097/YCO.0b013e3282f32408
   PubMed Web of Science ®Google Scholar
• Dhingra D, Kaur S, Ram J. Illicit drugs: effects on eye. Indian J Med Res. 2019;150:228–238. doi:10.4103/ijmr.IJMR_1210_17
   PubMed Web of Science ®Google Scholar
• Sarris J. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. Phytother Res. 2018;32:1147–1162. doi:10.1002/ptr.6055
   PubMed Web of Science ®Google Scholar
• Yeung KS, Hernandez M, Mao JJ, et al. Herbal medicine for depression and anxiety: a systematic review with assessment of potential psycho-oncologic relevance. Phytother Res. 2018;32:865–891. doi:10.1002/ptr.6033
   PubMed Web of Science ®Google Scholar
• Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry. 2003;64(Suppl 13):13–17.
   PubMedGoogle Scholar
• Gerhard DM, Wohleb ES, Duman RS. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today. 2016;21:454–464. doi:10.1016/j.drudis.2016.01.016
   PubMed Web of Science ®Google Scholar
• Zheng W, Cai DB, Xiang YQ, et al. Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord. 2020;265:63–70. doi:10.1016/j.jad.2020.01.002
   PubMed Web of Science ®Google Scholar
• García-Gutiérrez MS, Navarrete F, Gasparyan A, et al. Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules. 2020;10(11):1575. doi:10.3390/biom10111575
   PubMed Web of Science ®Google Scholar
• Yokoi Y, Narita Z, Sumiyoshi T. Transcranial direct current stimulation in depression and psychosis: a systematic review. Clin EEG Neurosci. 2018;49(2):93–102. doi:10.1177/1550059417732247
   PubMed Web of Science ®Google Scholar
• Salehpour F, Mahmoudi J, Kamari F, et al. Brain photobiomodulation therapy: a narrative review. Mol Neurobiol. 2018;55:6601–6636.
   PubMed Web of Science ®Google Scholar